TY  - JOUR
T1  - Cancer Intralesion Chemotherapy with Solasodine Rhamnosyl Glycosides
AU - , Bill E. Cham 
JO  - Research Journal of Biological Sciences
VL  - 3
IS  - 9
SP  - 1008
EP  - 1017
PY  - 2008
DA  - 2001/08/19
SN  - 1815-8846
DO  - rjbsci.2008.1008.1017
UR  - https://makhillpublications.co/view-article.php?doi=rjbsci.2008.1008.1017
KW  - Cancer
KW  -solasodine rhamnosyl glycosides
KW  -BEC
KW  -apoptosis
KW  -intralesion
AB  - Solasodine rhamnosyl glycosides (SRGs) are a new class of chemotherapeutic agents for the treatment of cancer. SRGs in a cream formulation Curaderm<SUP>BEC5</SUP> is now available for the treatment of skin cancers. Phase 2 clinical trials with intravenous (i.v.) administration of SRGs on patients with internal cancers are currently being done. The specificity and mode of action of SRGs are vastly different than those of other traditional anti-mitotic anticancer drugs. These differences have now led to SRGs intralesion chemotherapy, a very effective, new safer, anticancer modality, resulting in rapid regression of solid tumours using 1% of the dose that is required when compared with SRGs i.v. administration. In this feasibility pilot study large external tumours of animals and man were injected intralesionally with SRGs. Results demonstrate that SRGs when injected intralesionally successfully dispose of large tumours without any clinical adverse effects and that apoptosis is the cause of cancer cell death.
ER  -